[go: up one dir, main page]

TN2011000368A1 - Fused ring compound and use thereof - Google Patents

Fused ring compound and use thereof

Info

Publication number
TN2011000368A1
TN2011000368A1 TN2011000368A TN2011000368A TN2011000368A1 TN 2011000368 A1 TN2011000368 A1 TN 2011000368A1 TN 2011000368 A TN2011000368 A TN 2011000368A TN 2011000368 A TN2011000368 A TN 2011000368A TN 2011000368 A1 TN2011000368 A1 TN 2011000368A1
Authority
TN
Tunisia
Prior art keywords
fused ring
ring compound
activity
diseases
yagonistic
Prior art date
Application number
TN2011000368A
Other languages
English (en)
Inventor
Tsuyoshi Maekawa
Hideyuki Igawa
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of TN2011000368A1 publication Critical patent/TN2011000368A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
TN2011000368A 2009-01-30 2011-07-27 Fused ring compound and use thereof TN2011000368A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009020720 2009-01-30
PCT/JP2010/051651 WO2010087515A1 (fr) 2009-01-30 2010-01-29 Composé à noyaux condensés et son utilisation

Publications (1)

Publication Number Publication Date
TN2011000368A1 true TN2011000368A1 (en) 2013-03-27

Family

ID=42026435

Family Applications (1)

Application Number Title Priority Date Filing Date
TN2011000368A TN2011000368A1 (en) 2009-01-30 2011-07-27 Fused ring compound and use thereof

Country Status (36)

Country Link
US (4) US8283353B2 (fr)
EP (1) EP2384327B1 (fr)
JP (2) JP4892649B1 (fr)
KR (1) KR20110113758A (fr)
CN (2) CN102369205B (fr)
AR (1) AR075344A1 (fr)
AU (1) AU2010208863A1 (fr)
CA (1) CA2750710C (fr)
CL (1) CL2011001848A1 (fr)
CO (1) CO6362011A2 (fr)
CR (1) CR20110463A (fr)
CY (1) CY1114530T1 (fr)
DK (1) DK2384327T3 (fr)
DO (1) DOP2011000249A (fr)
EA (1) EA019823B1 (fr)
EC (1) ECSP11011294A (fr)
ES (1) ES2433225T3 (fr)
GE (1) GEP20135961B (fr)
HR (1) HRP20131017T1 (fr)
IL (1) IL214283A0 (fr)
MA (1) MA33071B1 (fr)
ME (1) ME01621B (fr)
MX (1) MX2011008058A (fr)
MY (1) MY152946A (fr)
NZ (1) NZ594606A (fr)
PE (1) PE20120593A1 (fr)
PL (1) PL2384327T3 (fr)
PT (1) PT2384327E (fr)
RS (1) RS53012B (fr)
SG (1) SG173135A1 (fr)
SI (1) SI2384327T1 (fr)
TN (1) TN2011000368A1 (fr)
TW (2) TWI468410B (fr)
UY (1) UY32409A (fr)
WO (1) WO2010087515A1 (fr)
ZA (1) ZA201105867B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY32409A (es) * 2009-01-30 2010-08-31 Takeda Pharmaceutical Compuesto de anillo fusionado y su uso
US8815853B2 (en) 2010-12-23 2014-08-26 Sanofi Pyrimidinone derivatives, preparation thereof and pharmaceutical use thereof
CZ304252B6 (cs) * 2011-04-11 2014-01-29 Zentiva, K. S. Způsob výroby 2-ethoxy-1-((2´-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)bifenyl-4-yl)methyl)-1H-benzo[d]imidazol-7-karboxylátů a jejich převedení na azilsartan
AU2017282871B2 (en) * 2016-06-20 2020-03-05 Novartis Ag Crystalline forms of triazolopyrimidine compound
AU2018342100B2 (en) 2017-09-26 2021-08-12 Ecolab Usa Inc. Acidic/anionic antimicrobial and virucidal compositions and uses thereof
EP3804712A4 (fr) 2018-05-31 2022-05-25 Hua Medicine (Shanghai) Ltd. Combinaison pharmaceutique contenant un activateur de glucose kinase et un activateur de récepteur ppar, composition, préparation de composé, son procédé de préparation et leurs utilisations
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020168197A1 (fr) 2019-02-15 2020-08-20 Incyte Corporation Composés de pyrrolo[2,3-d]pyrimidinone en tant qu'inhibiteurs de cdk2
WO2020180959A1 (fr) 2019-03-05 2020-09-10 Incyte Corporation Composés de pyrazolyl pyrimidinylamine en tant qu'inhibiteurs de cdk2
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
WO2020223558A1 (fr) 2019-05-01 2020-11-05 Incyte Corporation Composés aminés tricycliques en tant qu'inhibiteurs de cdk2
US11427567B2 (en) 2019-08-14 2022-08-30 Incyte Corporation Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors
CN119930610A (zh) 2019-10-11 2025-05-06 因赛特公司 作为cdk2抑制剂的双环胺
CN112745319B (zh) * 2019-10-30 2022-06-17 中国科学院上海药物研究所 一类取代三环结构的化合物、其制备方法及用途
EP4075976A1 (fr) 2019-12-16 2022-10-26 Ecolab USA Inc. Impact de tensioactif anionique sur l'efficacité virucide
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2672892B1 (fr) * 1991-02-20 1994-01-14 Synthelabo Derives de 4-pyrimidinones, leur preparation et leur application en therapeutique.
US5472967A (en) 1991-02-20 1995-12-05 Synthelabo 4-pyrimidinone derivatives their preparation and their application in therapy
TW251288B (fr) * 1991-06-27 1995-07-11 Takeda Dharm Industry Co Ltd
IL102183A (en) 1991-06-27 1999-11-30 Takeda Chemical Industries Ltd Biphenyl substituted heterocyclic compounds their production and pharmaceutical compositions comprising them
IT1250749B (it) * 1991-08-02 1995-04-21 Luso Farmaco Inst Composti eterociclici ad attivita' a ii antagonista
FR2687677B1 (fr) * 1992-02-24 1996-10-11 Union Pharma Scient Appl Nouveaux derives de polyazaindenes antagonistes des recepteurs a l'angiotensine ii ; leurs procedes de preparation, compositions pharmaceutiques les contenant.
US5387747A (en) 1992-02-24 1995-02-07 Laboratoires Upsa Triazolopyrimidine derivatives which are angiotensin II receptor antagonists, their methods of preparation and pharmaceutical compositions in which they are present
US5389632A (en) 1992-02-24 1995-02-14 Laboratoires Upsa Pyrazolopyrimidine derivatives which are angiotensin II receptor antagonists
IT1263804B (it) 1993-01-22 1996-09-03 Luso Farmaco Inst Derivati pirimidinonici fusi con eterocicli azotati ad attivita' a ii antagonista
GB9406573D0 (en) 1994-03-31 1994-05-25 Merck Sharp & Dohme Medicaments
AU5982296A (en) 1995-06-07 1996-12-30 G.D. Searle & Co. Method to treat cardiofibrosis with a combination of an angi otensin ii antagonist and spironolactone
DK0831911T3 (da) 1995-06-07 2002-07-22 Searle & Co Kombinationsterapi til behandling af kongestivt hjertesvigt med spironolacton og angiotensin II-antagonist
AU6039296A (en) 1995-06-07 1996-12-30 G.D. Searle & Co. Method to treat cardiofibrosis with a combination therapy of an angiotensin ii antagonist and an epoxy-steroidal aldoste rone antagonist
WO1996040257A1 (fr) 1995-06-07 1996-12-19 G.D. Searle & Co. Therapie mixte a base d'un antagoniste epoxy-steroidien de l'aldosterone et d'un antagoniste de l'angiotensine ii pour le traitement de l'insuffisance cardiaque globale
FR2812876B1 (fr) 2000-08-08 2002-09-27 Galderma Res & Dev Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppar-gamma et leur utilisation dans des compositions cosmetiques ou pharmaceutiques
SE0101579D0 (sv) 2001-05-04 2001-05-04 Astrazeneca Ab New compounds
US7232828B2 (en) 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
TW200418835A (en) 2003-01-24 2004-10-01 Tanabe Seiyaku Co A pyrazolopyrimidine compound and a process for preparing the same
WO2005020984A2 (fr) 2003-08-29 2005-03-10 Aaipharma Inc. Methode de reduction du stress oxydatif
US20060025383A1 (en) * 2004-02-03 2006-02-02 Neil Wishart Aminobenzoxazoles as therapeutic agents
AU2005250285B2 (en) 2004-06-02 2011-08-18 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
US20050288272A1 (en) 2004-06-23 2005-12-29 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and AT1 receptor antagonists
WO2006000564A1 (fr) 2004-06-23 2006-01-05 Solvay Pharmaceuticals Gmbh Compositions pharmaceutiques comprenant des inhibiteurs de l'epn, inhibiteurs du systeme de production de l'endotheline endogene et antagonistes du recepteur at1
CA2616150A1 (fr) 2005-07-27 2007-02-01 Talia Weinstein Inhibition du systeme renine-angiotensine pour le traitement de pathologies renales, vasculaires et cartilagineuses
WO2007053406A1 (fr) 2005-10-28 2007-05-10 Novartis Ag Combinaison de composes organiques hypotenseurs et hypocholesterolemiant
WO2007051007A2 (fr) 2005-10-28 2007-05-03 Novartis Ag Combinaison de composes organiques
US20080064871A1 (en) 2006-05-26 2008-03-13 Japan Tobacco Inc. Production Method of Nitrogen-Containing Fused Ring Compounds
US20090012052A1 (en) 2006-11-09 2009-01-08 Ore Pharmaceuticals Inc. Method for treating er+ breast cancer
CA2668725A1 (fr) 2006-11-09 2008-05-22 Ore Pharmaceuticals Inc. Procedes de depistage et de traitement du cancer du sein
US20080207654A1 (en) * 2006-11-24 2008-08-28 Takeda Pharmaceutical Company Limited Heteromonocyclic compound and use thereof
EP2151440A4 (fr) 2007-05-21 2010-10-20 Takeda Pharmaceutical Composé hétérocyclique et son utilisation
US20100221340A1 (en) 2007-09-20 2010-09-02 University Of Rochester Method and compositions for treatment or prevention of inflammatory conditions
CA2719457C (fr) 2008-03-24 2017-05-02 Novartis Ag Inhibiteurs de metalloproteases matricielles a base d'arylsulfonamides
US20110190373A1 (en) 2008-05-05 2011-08-04 University Of Rochester Methods and compositions for the treatment or prevention of pathological cardiac remodeling and heart failure
UY32409A (es) 2009-01-30 2010-08-31 Takeda Pharmaceutical Compuesto de anillo fusionado y su uso

Also Published As

Publication number Publication date
TWI468410B (zh) 2015-01-11
MA33071B1 (fr) 2012-02-01
EA019823B1 (ru) 2014-06-30
ECSP11011294A (es) 2011-09-30
ES2433225T3 (es) 2013-12-10
SG173135A1 (en) 2011-08-29
CN103788097B (zh) 2016-03-30
AU2010208863A1 (en) 2011-09-08
CN102369205B (zh) 2014-10-29
PE20120593A1 (es) 2012-05-21
US20110288087A1 (en) 2011-11-24
US8283353B2 (en) 2012-10-09
MY152946A (en) 2014-12-15
CN103788097A (zh) 2014-05-14
JP4892649B1 (ja) 2012-03-07
EP2384327A1 (fr) 2011-11-09
TW201031669A (en) 2010-09-01
US20100197683A1 (en) 2010-08-05
JP5676379B2 (ja) 2015-02-25
PT2384327E (pt) 2013-11-07
CA2750710A1 (fr) 2010-08-05
NZ594606A (en) 2013-06-28
DK2384327T3 (da) 2013-10-28
ME01621B (me) 2014-09-20
US8592431B2 (en) 2013-11-26
CN102369205A (zh) 2012-03-07
KR20110113758A (ko) 2011-10-18
MX2011008058A (es) 2011-09-01
SI2384327T1 (sl) 2013-12-31
HRP20131017T1 (hr) 2013-12-06
CL2011001848A1 (es) 2012-02-03
TW201444848A (zh) 2014-12-01
JP2011251970A (ja) 2011-12-15
PL2384327T3 (pl) 2013-12-31
US20110294832A1 (en) 2011-12-01
EA201101138A1 (ru) 2012-04-30
ZA201105867B (en) 2012-10-31
IL214283A0 (en) 2011-09-27
AR075344A1 (es) 2011-03-23
JP2012513952A (ja) 2012-06-21
US8921379B2 (en) 2014-12-30
UY32409A (es) 2010-08-31
EP2384327B1 (fr) 2013-07-31
GEP20135961B (en) 2013-11-11
HK1162505A1 (en) 2012-08-31
CR20110463A (es) 2011-12-01
DOP2011000249A (es) 2011-09-15
CA2750710C (fr) 2018-09-04
US9115136B2 (en) 2015-08-25
CO6362011A2 (es) 2012-01-20
CY1114530T1 (el) 2017-01-25
RS53012B (sr) 2014-04-30
US20140046056A1 (en) 2014-02-13
WO2010087515A1 (fr) 2010-08-05

Similar Documents

Publication Publication Date Title
TN2011000368A1 (en) Fused ring compound and use thereof
MY158982A (en) Heterocyclic compound
GEP20156216B (en) Heterocyclic compound and usage thereof
GEP20146124B (en) Novel ccr2 receptor antagonists and usage thereof
NZ601121A (en) 5-alkynyl-pyrimidines
GEP20146125B (en) Aminopyrimidines as syk inhibitors
TN2012000152A1 (en) Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes
MX2013001204A (es) Compuesto para el tratamiento/prevencion de enfermedades inflamatorias oculares.
IN2012DN00736A (fr)
HK1215579A1 (zh) 被取代的2，3-二氫苯並呋喃基化合物和其用途
GB0812642D0 (en) Compounds
NZ593004A (en) Azaazulene compounds
MX354021B (es) Derivados de 5-fluor-4-imino-3- (sustituido) -3,4-dihidropirimidin -2 (1h) ona.
MX2012002179A (es) Compuestos heterociclicos de oxima.
MY160785A (en) Manufacturing process for pyrimidine derivatives
UA102289C2 (ru) Гербициды, полученные из циклопентадиона
GEP20156319B (en) Asymmetric ureas and medical uses thereof
MX2011010449A (es) Derivados de oxadiazol.
EA201071229A1 (ru) Производные иминопиридина и их применение
EA201171339A1 (ru) Способ снижения внутриглазного давления у людей
JO3442B1 (ar) مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5)
IN2012DN00539A (fr)
MX339460B (es) Derivados de benzazol como ligandos del receptor h4 de histamina.
EP2602255A4 (fr) Composé à cycle hétérocyclique fusionné
IN2012DN00953A (fr)